3 results
Approved WMOCompleted
The feasibility of the new device is investigated. The primary objective includes the ability to regulate nocturnal PETCO2 in patients with CSAS and the user experiences. Secondary objectives concern the differences in CSAS parameters, e.g. apnea/…
Approved WMOWill not start
To assess the safety and tolerability profile of durvalumab monotherapy, durvalumab + novel oncology therapy, durvalumab + chemotherapy, anddurvalumab + novel oncology therapy + chemotherapy combinations
Approved WMOCompleted
To study the effect of apotransferrin administration in patients with β thalassemia intermedia on erythropoiesis as reflected by hemoglobin level or transfusion dependency. Secondary objectives are the effect of apotransferrin on the…